Overall Score

Revenue Model

Wave Life Sciences remains a pre-commercial biotech with no meaningful product revenue, so value is still driven by pipeline progress rather than recurring sales.

Gross margin remains structurally high on a low-revenue base, but the business model is not yet self-funding from operations.

Unit Economics

Unit economics are still dominated by R&D spend, with research and development to revenue at 3.02x and SG&A to revenue at 1.31x.

Negative operating and free cash flow margins remain the key constraint, although income quality is relatively high at 0.91.

Scalability

The model can scale if clinical programs convert to commercial assets, but current revenue per share is only 0.32 and asset turnover remains low at 0.12.

Very strong liquidity with a current ratio near 10.0 gives the company room to fund development, but it does not yet indicate operating leverage.

Capital Efficiency

Return metrics remain deeply negative, including ROIC at -0.43 and ROE at -0.50, showing capital is not yet being deployed profitably.

Balance-sheet leverage is modest, but the company is still burning cash and has not demonstrated durable capital efficiency.